The Effect of Menstration on GnRH Agonist Treatment for the Uterine Myoma

자궁근종의 성선자극호르몬분비호르몬 효능제 치료에 있어 생리의 영향

  • Han, Soo-Kyung (Department of Pharmacy, Chungnam National University Hospital) ;
  • Lee, Myung-Koo (College of Pharmacy, Chungbuk National University) ;
  • Han, Song-Yi (College of Pharmacy, Chungbuk National University) ;
  • Park, Mi-Sook (Department of Pharmacy, Chungnam National University Hospital) ;
  • Lim, Sung-Cil (College of Pharmacy, Chungbuk National University)
  • Published : 2007.12.31

Abstract

The aim of this study was to evaluate the effect of menstration among the influencing factors for the GnRH agonist (as G: depot goserelin 3.6 mg) therapy prior to the planned myomectomy for women who wanted to preserve their fertility. We reviewed total 48 patients. with the G therapy prior to the planned myomectomy from August 1st, 2005 to August 31st, 2006. The patients were classified by the G group (n=28) and the immediate surgery (as S) group (n=20). The G group (n=19) underwent the G therapy for 3 month courses, and then the efficacy was evaluated by menstruation and the myoma volumes. In the G group (n=19), therapy was effective, and the mean age was $32.4{\pm}6.5$ years. After the completion of G therapy, the mean volume of the myoma by ultrasonography was reduced to $85.2{\pm}71.2cm^3$ comparing of $430.6{\pm}248.8cm^3$ at first visit. The 11 patients had menstruation and the rest 8 patients with amenorrhea had less reduced volume of the myoma ($124.05{\pm}79.85cm^3\;v.s.\;329.41{\pm}234.0cm^3$ p<0.05). In the immediate S group, the myoma volumes by sonography was also checked for accuracy (${\alpha}=1.0$). As the result, the initial myoma volume had the positive correlations to the effectiveness with G therapy. However, the occurrence and frequency of the menstruation during the G therapy had a negative correlation. In conclusion, the use of G prior to the planned myomectomy was effective in reducing myoma volume and the menstruation.

References

  1. Stewart, E. A. : Uterine fibroids. Lancet. 357, 293 (2001) https://doi.org/10.1016/S0140-6736(00)03557-1
  2. Donnez, J. and Jadoul, E : What are the implications of myomas on fertility? A need for a debate? Hum. Reprod. 17,101 (2002)
  3. Lumsden, M. A. : The effects of steroid hormones on the growth of uterine leiomyomata. In: Motta, M. and Serio, M. eds. Sex hormones and antihormones in endocrine dependent pathology. Basic and clinical aspects. Excerpta Medica (1994)
  4. Burroughs, K. D., Fuchs-Young, R., Davis, B. and Walker, C. L.: Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol. Reprod. 63, 1322 (2000)
  5. Englund, K., Blanck, A., Gustavsson, I., Lundkvist, U., Sjoblom, P., Norgren, A. and Lindblom, B. : Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadatrophin-releasing hormone treatment. J. Clin. Endocrinol. Metab. 83, 4092 (1998)
  6. Sadan, O., Ginath, S., Sofer, D., Rotmensch, S., Debby, A., Glezerman, M. and Zakut, H. : The role of tamoxifen in the treatment of symptomatic uterine leiomyomata-a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 96, 183 (2001)
  7. Perry, C. M. and Brogden, R. N. : Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs. 51, 319 (1996)
  8. Donnez, J., Schrurs, B., Gillerot, S., Sandow, J. and Clerckx, E : Treatment of uterine fibroids with implants of gonadotrophin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 51, 947 (1989)
  9. Jonathan, S. B., Eli, Y. A. and Paula, A. H.: Novak's gynecology 12th. Williams & Wilkins, Baltimore, p. 374 (1996)
  10. Buttram, V C. Jr. and Reiter, R. C. : Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 36, 433 (1981)
  11. Lethaby, A., Vollenhoven, B. and Sowter, M. : Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane. Database. Syst. Rev. 2, CD000547 (2001)
  12. Kiiholma, E, Tuimala, R., Kivinen, S., Korhonen, M. and Hagman, E. : Comparison of the gonadotrophin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progesterone add-back therapy in the treatment of endometriosis. Fertil Steril. 64, 903 (1995)
  13. Kiesel, L. A., Rody, A., Greb, R. R. and Szilagyi, A. : Clinical use of GnRH analogues. Clin. Endocrinol. 56, 677 (2002)
  14. West, C. E, Lumsden, M. A., Lawson, S., Williamson, J. and Baird, D. T.: Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril. 48, 45 (1987)
  15. Cramer, S. E and Patel, A. : The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 94, 435 (1990)
  16. Marshall, L. M., Spiegelman, D., Barbieri, R. L., Goldman, M. B., Manson, J. E., Colditz, G. A., Willett, W C. and Hunter, D. J. : Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol. 90, 967 (1997)
  17. Garcia, C. R. and Tureck, R. W : Submucosal leiomyomas and infertility. Fertil Steril. 42, 16 (1984)
  18. Rice, J. E, Kay, H. H. and Mahony, B. S. ; The clinical significance of uterine leiomyomas in pregnancy. Am. J. Obstet. Gynecol. 160, 1212 (1989)
  19. Ross, R. K., Pike, M. C, Vessey, M. P., Bull, D., Yeates, D. and Casagrande, J. T. : Risk factors for uterine fibroids: reduced risk associated with oral contraceptives [published erratum in BMJ 1986; 293: 1027]. BMJ 293, 359 (1986)
  20. Paraziini, E, La Vecchia, C, Negri, E., Cecchetti, G. and Fedele, L. : Epidemiologic characteristics of women with uterine fibroids: a case control study. Obstet. Gynecol. 72, 853 (1988)
  21. Marshall, L. M., Spiegelman, D., Goldman, M. B., Manson, J. E., Colditz, G. A., Barbieri, R. L., Stampfer, M. J. and Hunter, D. J. : A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 70, 432 (1998)
  22. Kjerulff, K. H., Langenberg, P., Seidman, J. D., Stolley, R D. and Guzinski, G. M.: Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J. Reprod. Med. 41, 483 (1996)
  23. 김동호, 김홍관, 선진규, 박병삼, 임헌정 : 자궁근종에 대한 임상 및 병리학적 연구. 대한산부회지 37, 1205 (1994)
  24. 백원민, 정승우, 조성식, 임광호 : 자궁근종의 임상적 고찰. 대한산부회지 20, 1047 (1983)
  25. Filicori, M., Hall, D. A., Loughlin, J. S., Rivier, J., Vale, W. and Crowley, W. F. Jr.: A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am. J. Obstet. Gynecol. 147, 726 (1983)
  26. 정진국, 고만석, 정병욱, 이호형, 최호준, 신승권 : 자궁근종에 관한 임상통계학적 고찰. 대한산부회지 41, 210 (1998)
  27. 서호성, 남철, 김창수, 장병곤, 양희동, 박세준 : 자궁근종에 대한 임상통계학적 연구. 대한산부회지 39, 1047 (1996)
  28. 유한기 : 자궁근종의 임상병리학적 연구. 대한산부회지 30, 1287 (1987)
  29. 육순광, 정기성, 이숙환, 김성도, 안재영 : 자궁근종의 임상병리학적 고찰. 대한산부회지 27, 184 (1984)
  30. 이란옥, 박경일, 김종철, 박무실, 김철, 지정희 : 자궁근종에 대한 임상통계학적 관찰. 대한산부회지 30, 213 (1987)
  31. 이종학 : 자궁근종에 대한 임상적 및 병리학적 연구. 대한산부회지 30, 213 (1987)
  32. Cramer, S. F. and Patel, A. : The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 94, 435 (1990)
  33. Donnez, J., Nisolle, M., Grandjean, E, Gillerot, S. and Clerckx, E : The role of GnRH agonists in the endoscopic treatment of endometriosis and fibromyomas. Contracept. Fertil Sex. 21, 59 (1993)
  34. Early breast cancer trialists' collaborative group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 348, 1189 (1996)
  35. Pickersgill, A., Kingsland, C. R., Garden, A. S. and Farquharson, R. G.: Multiple gestation following gonadotrophin releasing hormone therapy for the treatment of minimal endometriosis. Br. J. Obstet. Gynaecol. 101, 260 (1994)
  36. Stovall, T. G., Muneyyirci-Delale, O., Summit, R. L. Jr. and Scialli, A. R. : GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet. Gynecol. 86, 64 (1995)
  37. Shaw, R. W : New approaches to the management of fibroids. Curr. Opin. Obstet. Gynecol. 3, 859 (1991)
  38. Carr, B. R., Marshburn, E B., Weatherall, E T, Bradshaw, K. D., Breslau, N. A., Byrd, W, Roark, M. and Steinkampf, M. E : An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J. Clin. Endocrinol. Metab. 76, 1217 (1993)
  39. Friedman, A. J., Barbieri, R. L., Doubilet, E M., Fine, C. and Schiff, I. : A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril. 49, 404 (1988)
  40. Friedman, A. J., Daly, M., Juneau-Norcross, M., Gleason, R., Rein, M. S. and LeBoff, M. : Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum. Reprod. 9, 1618 (1994)